MOUNTAIN VIEW, Calif., Nov. 29, 2016 /PRNewswire/ -- Cellecta, Inc. today announced the launch of Driver-Mapô Human Genome-Wide
(Photo - http://photos.prnewswire.com/prnh/20161128/443292-INFO)
The multiplex RT-PCR-based-, followed by next-generation sequencing (NGS), method applied in the Driver-Map Expression Profiling Service addresses the limitations in specificity, reproducibility and sensitivity of other genome-wide expression profiling approaches such as RNA-Seq and microarray platforms.
"The advanced methods now available to researchers through the Driver-Map Genome-Wide service will enable expression profiling of even the most complex samples such as those from xenografts, whole blood and tissue biopsies. We look forward to enabling a more efficient path to discovery of novel diagnostics and therapeutic agents for a wide variety of disease areas," said Alex Chenchik, Ph.D., founder and CEO of Cellecta.
The highly reproducible Driver-Mapô assay employs a robust, single-test-tube protocol which features unique improvements that are particularly suitable to complex applications such as large-scale biomarker discovery, tumor microenvironment characterization, and others which require minimal amounts of RNA sample. These improvements include:
The basic service includes extensive sample RNA quality control, the Driver-Mapô assay, next-generation sequencing to determine the relative number of transcripts of each gene, and comprehensive analysisó resulting in multiplex data that is annotated, normalized, with basic statistical analysis presented in the final report.
Driver-Mapô Human Genome-Wide Expression Profiling Service is available now. For more information, please visit www.driver-map.com
Cellecta, Inc., a leading provider of genomic products and services, is an industry leader in RNAi and CRISPR technologies for the discovery and characterization of novel therapeutic targets, and genetic profiling for biomarker discovery. Numerous scientific papers have been published citing Cellecta's functional genomics portfolio offering gene knockout and knockdown screens, custom and genome-wide RNAi and CRISPR libraries, cell engineering, RNAi and CRISPR construct services, and mutation and expression profiling of disease samples.
Cellecta, Inc. is headquartered in Mountain View, California. Further information about the company and its functional genomic products and services may be found online at www.cellecta.com
Paul Diehl, 650-938-4050 [email protected]
Media:Ruth Mercado, [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cellecta-inc-launches-driver-map-human-genome-wide-expression-profiling-service-for-19000-human-genes-300369533.html
SOURCE Cellecta, Inc.
Subscribe to our Free Newsletters!
Statins are a group of drugs which help to lower the blood cholesterol levels.
Niemann-Pick disease is a group of inherited metabolic disorders in which cholesterol and lipids ...
Raspberries are packed with important nutrients, vitamins and minerals. They help boost immunity, ...View All